UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 144 Filer Information

Form 144

FORM 144

NOTICE OF PROPOSED SALE OF SECURITIES

PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

144: Filer Information

Filer CIK 0001727477
Filer CCC XXXXXXXX
Is this a LIVE or TEST Filing? • LIVE • TEST

Submission Contact Information

Name Phone

E-Mail Address

144: Issuer Information

Name of Issuer ICU MEDICAL INC/DE

SEC File Number 001-34634

951 CALLE AMANECER

Address of Issuer

SAN CLEMENTE
CALIFORNIA
92763-6212

92763-6212 949-366-2183

Phone 949-366-2183

Name of Person for Whose Account the Securities are To Be Sold

Voigtlander Christian B.

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value			Securities
COMMON	Morgan Stanley Smith Barney LLC Executive Services 200 W Civic Center Dr - 4th Floor SANDY UT 84070	13603	1441918.00	24100000	03/04/2024	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Date you Nature of Name of Is Date Amount of Date of Nature of

Class	Acquired	Acquisition Transaction	Person from Whom Acquired	this Donor a Acquired Gift?	Securities Acquired	Payment	Payment *
COMMON	01/17/2020	PERFORMANCE SHARES	ISSUER		2489	01/17/2020 C	COMPENSATION
COMMON	03/06/2023	PERFORMANCE SHARES	ISSUER		4141	03/06/2023 C	COMPENSATION
COMMON	02/05/2017	RESTRICTED STOCK	ISSUER		681	02/05/2017 C	COMPENSATION
COMMON	03/06/2020	RESTRICTED STOCK	ISSUER		1240	03/06/2020 C	COMPENSATION
COMMON	03/27/2020	RESTRICTED STOCK	ISSUER		281	03/27/2020 C	COMPENSATION
COMMON	03/06/2021	RESTRICTED STOCK	ISSUER		1974	03/06/2021 C	COMPENSATION
COMMON	03/06/2023	RESTRICTED STOCK	ISSUER		735	03/06/2023 C	COMPENSATION
COMMON	03/07/2023	RESTRICTED STOCK	ISSUER		1016	03/07/2023	COMPENSATION
COMMON	03/08/2023	RESTRICTED STOCK	ISSUER		1046	03/08/2023	COMPENSATION

^{*} If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice 03/04/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature /s/ Christian Balceus Voigtlander

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)